[{"id":"88c8664d-c924-4f99-a910-6fbd85203e33","acronym":"VITILIMEL","url":"https://clinicaltrials.gov/study/NCT04920162","created_at":"2021-06-10T01:52:40.426Z","updated_at":"2024-07-02T16:35:20.005Z","phase":"","brief_title":"Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma","source_id_and_acronym":"NCT04920162 - VITILIMEL","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" BRAF","pipe":" | ","alterations":" CXCL9 expression • CXCL10 expression","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL9 expression • CXCL10 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-09"},{"id":"809a0473-89c4-4bc7-8faf-bd2441b7e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549833","created_at":"2021-01-18T12:20:05.485Z","updated_at":"2024-07-02T16:35:34.594Z","phase":"Phase 1","brief_title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","source_id_and_acronym":"NCT02549833","lead_sponsor":"Jennie Taylor","biomarkers":" CD8 • CXCL10 • CD4","pipe":" | ","alterations":" CXCL10 expression","tags":["CD8 • CXCL10 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL10 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GBM6-AD • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-05"}]